Drug intelligence / Profile preview

kaempferol-3-O-rutinoside

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Kaempferol-3-O-rutinoside (also known as nicotiflorin) is a natural flavonol glycoside found in various plants, including Solidago virgaurea (goldenrod) and Tetrastigma hemsleyanum. It exhibits a range of pharmacological activities, including anti-inflammatory, antioxidant, neuroprotective, and antineoplastic properties. In preclinical studies, kaempferol-3-O-rutinoside has been shown to inhibit the growth of human breast cancer cell lines (such as MCF-7 and MDA-MB-231) and lung adenocarcinoma cells (such as A549). Its mechanism of action in breast cancer involves the activation of AMPK (5' AMP-activated protein kinase) and the upregulation of FOXO3a, which subsequently induces the expression of the pro-apoptotic protein Bim, leading to G0/G1 cell cycle arrest and apoptosis. In lung cancer models, it has been shown to trigger cytoskeleton collapse, mitochondrial dysfunction, and calcium overload. Additionally, kaempferol-3-O-rutinoside binds to vascular endothelial growth factor C (VEGF-C), potentiating its anti-inflammatory effects in macrophages.

Other names
kaempferol 3-O-rutinosidekaempferol3-O-rutinosidekaempferol-3-O-rutinosidekaempferol 3-rutinosidekaempferol3-rutinosidekaempferol-3-rutinosidekaempferol-3-O-beta-rutinosidekaempferol3-O-beta-rutinosidekaempferol 3-O-beta-rutinosidenicotiflorinnicotiflorosidenictoflorin
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)AR (Adrenergic receptors)RPS6KA3 (RSK2)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)VEGFC (VEGF-C)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on kaempferol-3-O-rutinoside.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kaempferol-3-O-rutinoside.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call